Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 4
2014 1
2015 2
2016 2
2017 1
2018 3
2019 2
2020 2
2021 5
2022 8
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Response to the letter re: Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: A nationwide, population-based study.
Ben Khaled N, Mörtl B, Beier D, Reiter FP, Pawlowska-Phelan D, Teufel A, Rössler D, Schwade DF, Philipp A, Kubisch I, Ehmer U, Geier A, Lange CM, Mayerle J, Berger K, De Toni EN, Munker S. Ben Khaled N, et al. Among authors: munker s. Eur J Cancer. 2024 Feb;198:113499. doi: 10.1016/j.ejca.2023.113499. Epub 2023 Dec 15. Eur J Cancer. 2024. PMID: 38160177 No abstract available.
Concomitant Irradiation to Checkpoint Inhibitor Therapy of Hepatocellular Carcinoma Patients: A Systematic Retrospective, Single-Center Analysis.
Munker S, Roessler D, Öcal O, Ben-Khaled N, Bernhart K, Ye L, Piseddu I, Vielhauer J, Reiter FP, Rodriguez I, Ricke J, Teufel A, De Toni E, Seidensticker M, Niyazi M, Corradini S. Munker S, et al. Oncol Res Treat. 2023;46(11):466-475. doi: 10.1159/000533983. Epub 2023 Oct 12. Oncol Res Treat. 2023. PMID: 37827135 Free PMC article.
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study.
Ben Khaled N, Mörtl B, Beier D, Reiter FP, Pawlowska-Phelan D, Teufel A, Rössler D, Schwade DF, Philipp A, Kubisch I, Ehmer U, Geier A, Lange CM, Mayerle J, Berger-Thürmel K, De Toni EN, Munker S. Ben Khaled N, et al. Among authors: munker s. Eur J Cancer. 2023 Oct;192:113248. doi: 10.1016/j.ejca.2023.113248. Epub 2023 Jul 21. Eur J Cancer. 2023. PMID: 37672814
Positionspapier „Universitäre Karrierewege“.
Staudacher JJ, Backes M, Bettinger D, Blüthner E, Dietz-Fricke C, Dugic A, Fusco S, Garbe J, Goeser F, Guliyeva S, Hamesch K, Hollenbach M, Huber Y, Kasper P, Kocheise L, Langsch P, Leppkes M, Martens N, Mücke MM, Munker S, Murillo K, Nagl S, Sanoubara F, Sturm N, Stathopoulos P, Storck K, Sulzer S, Thiel-Bodenstaff A, Tran F, Wiessner JR, Willuweit K, Yaqubi K, Zeidler C, Schlosser S; für die universitäre JuGa. Staudacher JJ, et al. Among authors: munker s. Z Gastroenterol. 2023 Aug;61(8):997-999. doi: 10.1055/a-2116-6308. Epub 2023 Aug 11. Z Gastroenterol. 2023. PMID: 37567237 German. No abstract available.
The inhibition of YAP Signaling Prevents Chronic Biliary Fibrosis in the Abcb4-/- Model by Modulation of Hepatic Stellate Cell and Bile Duct Epithelium Cell Pathophysiology.
Ye L, Ziesch A, Schneider JS, Ofner A, Nieß H, Denk G, Hohenester S, Mayr D, Mahajan UM, Munker S, Khaled NB, Wimmer R, Gerbes AL, Mayerle J, He Y, Geier A, Toni EN, Zhang C, Reiter FP. Ye L, et al. Among authors: munker s. Aging Dis. 2024 Feb 1;15(1):338-356. doi: 10.14336/AD.2023.0602. Aging Dis. 2024. PMID: 37307826 Free PMC article.
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN. Ben Khaled N, et al. Among authors: munker s. Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240. Cancers (Basel). 2022. PMID: 36358659 Free PMC article.
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D, Öcal O, Philipp AB, Markwardt D, Munker S, Mayerle J, Jochheim LS, Hammer K, Lange CM, Geier A, Seidensticker M, Reiter FP, De Toni EN, Ben Khaled N. Roessler D, et al. Among authors: munker s. J Cancer Res Clin Oncol. 2023 Jul;149(7):3065-3073. doi: 10.1007/s00432-022-04206-8. Epub 2022 Jul 21. J Cancer Res Clin Oncol. 2023. PMID: 35864269 Free PMC article.
37 results